Zobrazeno 1 - 10
of 81
pro vyhledávání: '"A. P. Aleksankin"'
Autor:
A. V. Martynova, T. V. Popkova, A. P. Aleksankin, G. I. Gridneva, E. V. Gerasimova, Yu. N. Gorbunova, A. M. Lila
Publikováno v:
Современная ревматология, Vol 16, Iss 1, Pp 38-45 (2022)
Objective: assessment of the dynamics of T- and B-lymphocytes subpopulations in rheumatoid arthritis (RA) during therapy with synthetic disease-modifying antirheumatic drugs (sDMARDs) and biological disease-modifying antirheumatic drugs (bDMARDs): in
Externí odkaz:
https://doaj.org/article/17ef735ea5fa4fdd81c88ecfb2655910
Autor:
A. V. Martynova, T. V. Popkova, A. P. Aleksankin, G. I. Gridneva, E. V. Gerasimova, Yu. N. Gorbunova, A. S. Semashko, A. M. Lila
Publikováno v:
Современная ревматология, Vol 15, Iss 2, Pp 17-22 (2021)
Objective: to evaluate changes in T- and B-lymphocyte subpopulations at different stages of rheumatoid arthritis (RA).Patients and methods. The study included 53 patients with a definite RA diagnosis according to the 2010 ACR/EULAR criteria (mean age
Externí odkaz:
https://doaj.org/article/f16451cc9d3447f5aab95e789336a9f3
Autor:
L. P. Ananyeva, L. A. Garzanova, O. A. Koneva, M. N. Starovoytova, O. V. Desinova, O. B. Ovsyannikova, R. U. Shayakhmetova, M. V. Cherkasova, A. P. Aleksankin, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 60, Iss 1 (2022)
The aim of our study was to assess the relationship between the changes of antinuclear autoantibodies (ANA) and autoantibodies to topoisomerase 1 (anti-Topo 1) in systemic sclerosis (SSc) patients on rituximab (RTX) therapy.Materials and methods. The
Externí odkaz:
https://doaj.org/article/8e773ad2e104498cbd62816d673a14cb
Autor:
L. P. Ananyeva, O. A. Koneva, O. V. Desinova, L. A. Garzanova, S. I. Glukhova, M. N. Starovoitova, O. B. Ovsyannikova, A. V. Volkov, A. P. Aleksankin, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 3, Pp 265-273 (2019)
The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of s
Externí odkaz:
https://doaj.org/article/fb2372c816e44d50a10380459139c10a
Autor:
A. A. Mesnyankina, S. K. Solovyev, E. A. Aseeva, A. P. Aleksankin, E. N. Aleksandrova, E. L. Nasonov
Publikováno v:
Современная ревматология, Vol 13, Iss 1, Pp 35-43 (2019)
Objective: to evaluate the effect of different biological agents (BAs), including rituximab (RTM) and belimumab (BLM) combination therapy, on B-lymphocyte subpopulations during a follow-up of patients with systemic lupus erythematosus (SLE).Patients
Externí odkaz:
https://doaj.org/article/5fddb8487ffd492c9c81448d174933e5
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 6, Pp 731-738 (2019)
The clinical efficacy and safety of interleukin-6 (IL-6) receptor blockade have been well studied, but the data on the impact of therapeutic inhibition of IL-6 on B cells are scarce and contradictory. Preliminary reports have shown that B cell functi
Externí odkaz:
https://doaj.org/article/6ca38df7e75c4cd9abdffff1b1bf54dd
Autor:
A. S. Avdeeva, Yu. P. Rubtsov, T. V. Popkova, D. T. Dyikanov, A. P. Aleksankin, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 4, Pp 423-428 (2018)
Objective: to analyze the levels of CD3+, CD3+CD4+, CD3+CD8+, and CD3-CD56+ T lymphocytes, FoxP3+ regulatory T cells (Treg), and CD19+ B lymphocytes in patients with early and advanced rheumatoid arthritis (RA). Subjects and methods. The investigatio
Externí odkaz:
https://doaj.org/article/6dc420dd8519462a9e5bda78fe084fa3
Autor:
A. A. Mesnyankina, S. K. Solovyev, E. N. Aleksandrova, A. P. Aleksankin, E. V. Suponitskaya, A. V. Elonakov, E. A. Aseeva, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 55, Iss 3, Pp 252-260 (2017)
Objective: to study the baseline level and time course of changes in peripheral blood B cell subpopulations in patients with systemic lupus erythematosus (SLE) versus the clinical manifestations of the disease during therapy with rituximab (RTM) and
Externí odkaz:
https://doaj.org/article/67d32a1d995548d8a2dba5cd6cb8caf1
Autor:
A. A. Mesnyankina, S. K. Solovyev, E. N. Aleksandrova, A. P. Aleksankin, E. A. Aseeva, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 3, Pp 281-288 (2016)
Objective: to determine the efficiency of dual anti-B cell therapy in patients with active systemic lupus erythematosus (SLE).Subjects and methods. The clinic of the V.A. Nasonova Research Institute of Rheumatology followed up three patients with sig
Externí odkaz:
https://doaj.org/article/661f905dacb349899a6265edd6f34f58
Publikováno v:
Научно-практическая ревматология, Vol 53, Iss 1, Pp 78-83 (2015)
The paper considers the mechanisms of action of biological agents and their effect on peripheral blood B-lymphocyte subpopulations in patients with systemic lupus erythematosus and rheumatoid arthritis.
Externí odkaz:
https://doaj.org/article/11dd0016f0cb405198c0e872c888bf4b